- Home
- LXEH vs SLGL Comparison
LXEH vs SLGL Comparison
Compare LXEH & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- SLGL
- Stock Information
- Founded
- LXEH 2001
- SLGL 1997
- Country
- LXEH China
- SLGL Israel
- Employees
- LXEH N/A
- SLGL N/A
- Industry
- LXEH Other Consumer Services
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- SLGL Health Care
- Exchange
- LXEH Nasdaq
- SLGL Nasdaq
- Market Cap
- LXEH 25.1M
- SLGL 21.1M
- IPO Year
- LXEH 2020
- SLGL 2018
- Fundamental
- Price
- LXEH $1.86
- SLGL $7.24
- Analyst Decision
- LXEH
- SLGL Buy
- Analyst Count
- LXEH 0
- SLGL 1
- Target Price
- LXEH N/A
- SLGL $40.00
- AVG Volume (30 Days)
- LXEH 304.7K
- SLGL 13.2K
- Earning Date
- LXEH 06-17-2025
- SLGL 05-23-2025
- Dividend Yield
- LXEH N/A
- SLGL N/A
- EPS Growth
- LXEH N/A
- SLGL N/A
- EPS
- LXEH N/A
- SLGL N/A
- Revenue
- LXEH $4,493,795.00
- SLGL $12,103,000.00
- Revenue This Year
- LXEH N/A
- SLGL N/A
- Revenue Next Year
- LXEH N/A
- SLGL $31.17
- P/E Ratio
- LXEH N/A
- SLGL N/A
- Revenue Growth
- LXEH N/A
- SLGL 603.66
- 52 Week Low
- LXEH $1.53
- SLGL $3.34
- 52 Week High
- LXEH $50.08
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- LXEH 33.60
- SLGL 50.26
- Support Level
- LXEH $1.91
- SLGL $7.15
- Resistance Level
- LXEH $2.10
- SLGL $7.45
- Average True Range (ATR)
- LXEH 0.25
- SLGL 0.32
- MACD
- LXEH 0.37
- SLGL -0.10
- Stochastic Oscillator
- LXEH 22.41
- SLGL 31.36
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.